BriaCell Therapeutics Corp.
BCTX Nasdaq
SEC CIK 1610820
Follow BriaCell Therapeutics Corp.
Weekly email: filings, results
Net income
−$12.3M
−52.3% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$6M
+26.7% vs same quarter last year
Operating income
−$12.6M
−47.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY26 | −$34.9M |
| FY25 | −$26.3M |
| FY24 | −$4.8M |
| FY23 | −$20.3M |
| FY22 | −$26.8M |
| FY21 | −$13.8M |
| FY20 | - |